Recent studies showed that both of these two polymorphisms may affect individual susceptibility to metabolic disease and CHD risk, but there have also been studies which found that C161T PPARG slightly increased the sensitivity of coronary heart disease, and the P12A PPARG was not associated with the risk of CHD [100]. This evidence concerns the gene PPARG and Other metabolic disease.